These findings support the potential of both PD‐1 and PD‐L1 inhibitors to improve survival outcomes in SCLC patients when used in conjunction with chemotherapy, aligning with observations from the CheckMate 032 trial [23]. Here, CD274 is linked to small cell lung carcinoma.